JP2023550311A5 - - Google Patents
Info
- Publication number
- JP2023550311A5 JP2023550311A5 JP2023528113A JP2023528113A JP2023550311A5 JP 2023550311 A5 JP2023550311 A5 JP 2023550311A5 JP 2023528113 A JP2023528113 A JP 2023528113A JP 2023528113 A JP2023528113 A JP 2023528113A JP 2023550311 A5 JP2023550311 A5 JP 2023550311A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063109305P | 2020-11-03 | 2020-11-03 | |
| US63/109,305 | 2020-11-03 | ||
| US202163239108P | 2021-08-31 | 2021-08-31 | |
| US63/239,108 | 2021-08-31 | ||
| PCT/US2021/072193 WO2022099257A1 (en) | 2020-11-03 | 2021-11-02 | Use of isatuximab for the treatment of multiple myeloma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023550311A JP2023550311A (ja) | 2023-12-01 |
| JPWO2022099257A5 JPWO2022099257A5 (https=) | 2024-11-13 |
| JP2023550311A5 true JP2023550311A5 (https=) | 2024-11-13 |
Family
ID=78825149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528113A Pending JP2023550311A (ja) | 2020-11-03 | 2021-11-02 | 多発性骨髄腫の処置のための、イサツキシマブの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220135696A1 (https=) |
| EP (1) | EP4240416A1 (https=) |
| JP (1) | JP2023550311A (https=) |
| AU (1) | AU2021376374A1 (https=) |
| CA (1) | CA3197381A1 (https=) |
| IL (1) | IL302640A (https=) |
| TW (1) | TW202233235A (https=) |
| WO (1) | WO2022099257A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| KR20210006321A (ko) * | 2018-01-12 | 2021-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 항-cd38 항체의 피하 투여 |
| US11939390B2 (en) * | 2019-01-28 | 2024-03-26 | Sanofi-Aventis U.S. Llc | Methods of treating multiple myeloma |
| WO2020212912A1 (en) * | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses |
| US20210171650A1 (en) * | 2019-05-14 | 2021-06-10 | Sanofi | Methods of administering anti-cd38 antibody |
-
2021
- 2021-11-02 IL IL302640A patent/IL302640A/en unknown
- 2021-11-02 US US17/517,567 patent/US20220135696A1/en active Pending
- 2021-11-02 CA CA3197381A patent/CA3197381A1/en active Pending
- 2021-11-02 TW TW110140853A patent/TW202233235A/zh unknown
- 2021-11-02 AU AU2021376374A patent/AU2021376374A1/en active Pending
- 2021-11-02 JP JP2023528113A patent/JP2023550311A/ja active Pending
- 2021-11-02 EP EP21820805.6A patent/EP4240416A1/en active Pending
- 2021-11-02 WO PCT/US2021/072193 patent/WO2022099257A1/en not_active Ceased